Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations

被引:397
作者
Jankovic, J
机构
[1] Baylor Coll Med, Parkinsons Dis Ctr, Houston, TX 77030 USA
[2] Baylor Coll Med, Movement Disorders Clin, Dept Neurol, Houston, TX 77030 USA
关键词
motor complications; Parkinson's disease; dyskinesia; wearing off; levodopa;
D O I
10.1002/mds.20458
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Fluctuations in the symptoms of Parkinson's disease (PD), such as wearing-off and on-off effects, and dyskinesias are related to a variety of factors, including duration and dosage of levodopa, age at onset, stress, sleep, food intake, and other pharmacokinetic and pharmacodynamic mechanisms. The majority of patients, particularly those with young onset of PD, experience these levodopa-related adverse effects after a few years of treatment. Assessment of these motor complications is difficult because of the marked clinical variability between and within patients. Daily diaries have been used in clinical trials designed to assess the effects of various pharmacological and surgical interventions on motor fluctuations and dyskinesias. The most common type of dyskinesia, called "peak-dose dyskinesia", usually consists of stereotypical choreic or ballistic movements involving the head, trunk, and limbs, and occasionally, the respiratory muscles, whereas tremor and punding are less-common complications. Dystonia is also typically seen in patients with diphasic dyskinesia and wearing-off effect. Recognition of the full spectrum of clinical phenomenology of levodopa-related motor complications is essential for their treatment and prevention. (c) 2005 Movement Disorder Society.
引用
收藏
页码:S11 / S16
页数:6
相关论文
共 69 条
[1]   Slowing Parkinson's disease progression - Recent dopamine agonist trials [J].
Ahlskog, JE .
NEUROLOGY, 2003, 60 (03) :381-389
[2]   Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature [J].
Ahlskog, JE ;
Muenter, MD .
MOVEMENT DISORDERS, 2001, 16 (03) :448-458
[3]  
[Anonymous], 1996, Ann Neurol, V39, P37
[4]  
Bédard PJ, 1999, MOVEMENT DISORD, V14, P4
[5]   Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease - A multicenter 5-year study [J].
Block, G ;
Liss, C ;
Reines, S ;
Irr, J ;
Nibbelink, D ;
Aarli, J ;
Aguilar, M ;
Ahrens, S ;
Bakheit, A ;
Baumel, B ;
Bertoni, J ;
Capildeo, R ;
CastroCaldas, A ;
Deza, L ;
Donaldson, I ;
Franck, G ;
Fusillo, J ;
Gauthier, S ;
Gershanik, O ;
Granerus, AK ;
Hauser, RA ;
Hennessey, K ;
Hutton, JT ;
Joffe, R ;
Koller, W ;
Last, B ;
LeWitt, P ;
Mamoli, B ;
Manyam, B ;
Mark, M ;
Nakano, K ;
Nausieda, P ;
Otero, E ;
Paulson, G ;
Pinter, M ;
Reich, S ;
Rodnitzky, R ;
Sage, J ;
Sampaio, C ;
Smith, B ;
Teravainen, H ;
Tetrud, J ;
Tolosa, E ;
Ulm, G ;
Valesco, F .
EUROPEAN NEUROLOGY, 1997, 37 (01) :23-27
[6]   WEARING-OFF FLUCTUATIONS IN PARKINSONS-DISEASE - CONTRIBUTION OF POSTSYNAPTIC MECHANISMS [J].
BRAVI, D ;
MOURADIAN, MM ;
ROBERTS, JW ;
DAVIS, TL ;
SOHN, YH ;
CHASE, TN .
ANNALS OF NEUROLOGY, 1994, 36 (01) :27-31
[7]   Dopamine dysregulation syndrome in Parkinson's disease [J].
Evans, AH ;
Lees, AJ .
CURRENT OPINION IN NEUROLOGY, 2004, 17 (04) :393-398
[8]  
Fahn S, 2000, ANN NEUROL, V47, pS2
[9]   Parkinson disease, the effect of levodopa, and the ELLDOPA trial [J].
Fahn, S .
ARCHIVES OF NEUROLOGY, 1999, 56 (05) :529-535
[10]  
Fahn S, 2002, MOVEMENT DISORD, V17, pS13